
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Phenobarbital Sodium
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : SPARC’s phenobarbital sodium powder for injection is a benzyl alcohol and propylene glycol-free formulation intended for the treatment of seizures in neonates.
Product Name : Phenobarbital Sodium-Generic
Product Type : Controlled Substance
Upfront Cash : $10.0 million
November 09, 2022
Lead Product(s) : Phenobarbital Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Levetiracetam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Tripoint Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Sparc Licenses Commercialization Rights of Elepsia Drug to Tripoint Therapeutics
Details : Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for ElepsiaTM XR 1000 mg and El...
Product Name : Elepsia
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 22, 2020
Lead Product(s) : Levetiracetam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Tripoint Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SCD-044
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : $145.0 million
Deal Type : Licensing Agreement
SPARC, Sun Pharma Ink Pact to Develop & Commercialize SCD-044 to Treat Inflammatory Diseases
Details : Sun Pharma has been granted a worldwide licence for the development and commercialization of SCD-044, which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 cli...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $20.0 million
May 29, 2020
Lead Product(s) : SCD-044
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : $145.0 million
Deal Type : Licensing Agreement
